Cargando…
Stem Cell-Based Clinical Trials for Diabetes Mellitus
Since its introduction more than twenty years ago, intraportal allogeneic cadaveric islet transplantation has been shown to be a promising therapy for patients with Type I Diabetes (T1D). Despite its positive outcome, the impact of islet transplantation has been limited due to a number of confoundin...
Autores principales: | de Klerk, Eleonora, Hebrok, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953062/ https://www.ncbi.nlm.nih.gov/pubmed/33716982 http://dx.doi.org/10.3389/fendo.2021.631463 |
Ejemplares similares
-
Multiplexed microfluidic platform for stem-cell derived pancreatic islet β cells
por: Goswami, Ishan, et al.
Publicado: (2022) -
Mesenchymal Stem Cell-Based Treatment for Microvascular and Secondary Complications of Diabetes Mellitus
por: Davey, Grace C., et al.
Publicado: (2014) -
The roles of mesenchymal stem cell-derived exosomes in diabetes mellitus and its related complications
por: Yang, Mengmeng, et al.
Publicado: (2022) -
Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement
por: Wan, Xin-Xing, et al.
Publicado: (2022) -
VHL-mediated disruption of Sox9 activity compromises β-cell identity and results in diabetes mellitus
por: Puri, Sapna, et al.
Publicado: (2013)